Peer-reviewed veterinary case report
Pharmacological ascorbate effects and blood levels in healthy Beagle
By Musser, Margaret L et al.·Published in Frontiers in veterinary science·2019·Iowa State University, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Cytotoxicity and Pharmacokinetic Evaluation of Pharmacological Ascorbate in Dogs.
- Species:
- dog
Plain-English summary
A group of healthy Beagle dogs received high doses of a vitamin C treatment (pharmacological ascorbate) to see how it affected their bodies and canine cancer cells. The dogs were given two different doses through an IV, and their blood levels of vitamin C were monitored. The results showed that the treatment reached high levels in the dogs' blood and was mostly safe, with only minor side effects in a couple of them. In lab tests, the vitamin C significantly reduced the survival of certain cancer cells, suggesting it could be a promising option for treating canine cancer in the future.
People also search for: dog cancer treatment vitamin C · Beagle osteosarcoma study · high-dose vitamin C for dogs
Abstract
High-dose, pharmacological ascorbate (P-AscH) is preferentially cytotoxic to human cancer cells. Investigations on the efficacy of P-AscHas an adjuvant treatment for multiple human cancers are on-going, but has yet to be formally investigated in dogs. The primary objectives of this study were to determine the pharmacokinetic (PK) profile of P-AscHin healthy Beagle dogs and the effects of P-AscHon canine osteosarcoma cells.Eight purpose-bred, healthy, spayed female Beagle dogs, between 20 and 21 months old, and 8-10 kg were administered two doses of P-AscH(550 or 2,200 mg/kg)intravenous infusion over 6 h, on separate days. Plasma ascorbate concentrations were measured at 12 time points during and after infusion for PK analysis using nonlinear mixed-effects (NLME) and non-compartmental analysis (NCA). Clonogenic assays were performed on 2 canine osteosarcoma cell lines (D-17 and OSCA-8) and canine primary dermal fibroblasts after exposure to high concentrations of ascorbate (75 pmoles/cell).Plasma ascorbate levels in the dogs peaked at approximately 10 mM following 2,200 mg/kg and returned to baseline 6-8 h after dosing. Minor adverse effects were seen in two dogs. Ascorbate (75 pmoles/cell) significantly decreased survival in both the osteosarcoma cell lines (D-17 63% SD 0.010,= 0.005; OSCA-8 50% SD 0.086,= 0.026), compared to normal fibroblasts (27% SD 0.056).Pharmacological ascorbate is preferentially cytotoxic to canine-derived cancer cells. High levels of ascorbate can be safely administered to dogs. Further studies are needed to determine the effects of P-AscHon canine patients.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/31788483/